Connect with us

Legal & Regulation

A Proposed Amendment to Psychedelics Continues Onward Yet Cannabis Proposal Gets Denied

Published

on

A Proposed Amendment to Psychedelics Continues Onward Yet Cannabis Proposal Gets Denied

Currently, both cannabis and psilocybin are illegal under federal law and are Schedule I substances, and as such, researchers also cannot study the substances. A proposed amendment to a large-scale spending bill that funds portions of the government during the 2020 Fiscal Year, introduced by Representative Alexandria Ocasio-Cortez (D-NY), may have a significant impact on the study of psilocybin and MDMA. Psilocybin is the active compound in “magic shrooms,” while MDMA is ecstasy. According to the proposed amendment, these substances have “shown promise in end of life therapy and treating PTSD.”

If the amendment is approved, a provision to the spending bill that prohibits spending federal funds on “any activity that promotes the legalization of any drug or other substance in Schedule I” of the Controlled Substances Act would be eliminated, thus paving the way for research.

Ocasio-Cortez tweeted about the amendment, stated “From the opioid crisis to psilocybin’s potential w/ PTSD, it’s well past time we take drug use out of criminal consideration + into medical consideration. That begins with research. I’m proud to introduce an amendment that helps scientists do their jobs.”

Another amendment was filed by Rep. Lou Correa (D-CA) concerning the spending bill. His amendment would prevent the Department of Education from moving “to deny or limit any funding or assistance to institutions of higher education” allowing for the use or possession of medical marijuana in states where the substance has been legalized. Pedro Padilla, the University of Utah NORML Director, shared with Marijuana Moment, “It is frustrating that patients who are seeking to improve their position in life by attending college would be forced to choose between their education and their medication.”

All information is for general informational and educational purposes only. Nothing should be interpreted as legal or wellness advice.

Jane is a regular contributor who learned about the great benefits of CBD a few years ago after starting it herself. Impressed by its effects, she's interested in helping others learn about options that can be helpful for them.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.